admin, Autore presso Adres

Implantation of Reveal LINQ in Different Italian Scenarios: How to Further Improve?

Senatore G., Di Lorenzo E., Zaniolo O., Liuzzi G. – Farmeconomia. Health economics and therapeutic pathways 2024; 25(1): 19-29

Optimizing Treatment of Schizophrenia: Clinical and Economical Potential for Patient Switching to Long‑Acting Injectables

Zaniolo O., Maffezzoli S., Povero M., Pradelli L. – Farmeconomia. Health economics and therapeutic pathways 2024; 25(1): 9-17

Cost per Responder Analysis of Filgotinib in Patients Suffering from Ulcerative Colitis

Povero M., Castello L., Pradelli L., Visentin E. – Farmeconomia. Health economics and therapeutic pathways 2024; 25(1): 1-7

Pharmacoeconomics: Principles and Practice

Resource constraints in healthcare and the increasing costs of new treatments have prompted the resorting to pharmacoeconomic studies. New techniques allow to tailor to the specificity of each situation, thus giving back accurate calculations and estimations. The desire to publish a more updated version of “Pharmacoeconomics. Principle and Practice” fits into this frame and provide […]

Elementi di biostatistica ed epidemiologia clinica per l’analisi degli studi osservazionali

Questa guida è stata scritta con l’obiettivo di favorire, in modo semplice e intuitivo e partendo dalla research question, la comprensione dei più importanti concetti di biostatistica ed epidemiologia clinica relativi agli studi osservazionali. Inoltre, attraverso una serie di esempi pratici focalizzati sul “come fare”, questa pocket guide intende rappresentare uno strumento di facile e […]

Real World Evidence e farmaci

Con “Real World Evidence” si intendono le evidenze cliniche sull’utilizzo e i possibili effetti di una terapia così come risultano dall’analisi dei dati tratti dalla pratica clinica (i cosiddetti “Real World Data”). Negli ultimi anni i dati di Real World Evidence sono sempre più utilizzati dai diversi stakeholders: dalle aziende farmaceutiche per la ricerca & […]

Pharmaceutical Market Access in Developed Markets

Il market access è il processo tramite il quale una compagnia farmaceutica, dopo aver ottenuto l’autorizzazione all’immissione in commercio da parte dell’agenzia regolatoria, rende il proprio prodotto disponibile sul mercato per tutti i pazienti per i quali il farmaco ha ottenuto l’indicazione. Il processo di market access comprende un gruppo di attività volto a fornire […]

Pharmaceutical Market Access in Emerging Markets

Negli ultimi anni gli investimenti per i nuovi farmaci immessi sul mercato dei paesi emergenti si sono rivelati vincenti e oggi questi mercati rappresentano un’importante opportunità per il lancio di nuovi farmaci da parte delle multinazionali farmaceutiche. L’introduzione sul mercato di un nuovo farmaco richiede un’efficace strategia di market access, cioè di quell’insieme di attività […]

Translating Clinical Trial Outcomes Measures

Lo scopo di questo libro è fornire una panoramica generale sul processo di traduzione e adattamento culturale degli strumenti di survey utilizzati nella ricerca clinica con particolare evidenza sugli aspetti linguistici del processo. Gli strumenti di indagine a cui si fa riferimento comprendono qualsiasi testo, stampato o elettronico, preparato al fine di raccogliere informazioni in […]

Patient Reported Outcomes

I Patient Reported Outcomes (PRO) sono misurazioni che permettono di valutare la condizione di salute del paziente attraverso il punto di vista del paziente stesso, senza correzioni o interpretazioni da parte di intermediari. Strumenti PRO validi e affidabili sono in grado di fornire una misura standardizzata e quantificabile del beneficio di un trattamento sulla quale […]

Applied Epidemiology And Biostatistics

Questo libro si propone di affrontare non solo la teoria, ma di guidare il lettore ad applicare aspetti specifici di discipline tecniche quali l’epidemiologia e la biostatistica nella pratica clinica. Infatti ogni capitolo presenta uno o più esempi specifici su come realizzare un’analisi epidemiologica o statistica e fornisce al lettore la possibilità di riprodurre l’analisi […]

Economic Consequences of Administering Obinutuzumab as a Short Duration Infusion in Italian Patients with Advanced Follicular Lymphoma: A Cost Analysis

Bellone M., Pradelli L., Tavarozzi R., Ladetto M., Nepoti G. , E. Guardalben, D. Ghislieri. – Farmeconomia. Health economics and therapeutic pathways 2022; 23(1): 85-95

Cost-effectiveness of Empagliflozin, in Addition to Metformin, in Patients with Type 2 Diabetes in Italy

Mannucci E., Ghetti G. – Farmeconomia. Health economics and therapeutic pathways 2022; 23(1): 85-95

Budget Saving Potential of Pegfilgrastim Biosimilar for the Treatment of Chemotherapy-Induced Febrile Neutropenia, in Italy

Berto P., Bellone M., Sabinot A., Pinto C., Martino M., Generali D., Carriero P. L., Sanna M. D. – Farmeconomia. Health economics and therapeutic pathways 2022; 23(1): 1-12

Budget Impact Analysis of the Adjuvanted Quadrivalent Influenza Vaccine in the Elderly in Italy

Baldo V., Bellone M. – Farmeconomia. Health economics and therapeutic pathways 2022; 23(1): 69-83

Gestione del paziente affetto da diabete mellito T2: la presa in carico ottimizzata

Celeste Berra C. C., Pradelli L. – Farmeconomia. Health economics and therapeutic pathways 2021; 22(S2): 1-16

The contribution of patients’ lung function to the inspiratory airflow rate achievable through a DPIs’ simulator reproducing different intrinsic resistance rates

Dal Negro R W, Turco P, Povero M. – Multidis Res Med 2021 Apr.15;16

Assessing the global usability of dry powder inhalers: analysis of six devices widely used for asthma

Dal Negro R W, Turco P, Povero M. – J Pulm Med Respir Res 2021

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma

Carpagnano GE, Resta E, Povero M, Pelaia C, D’Amato M, Crimi N, Scichilone N, Scioscia G, Resta O, Calabrese C, Pelaia G, Barbaro – Sci Rep. 2021 Mar

Preliminary cost-effectiveness and cost-utility analysis of cemiplimab in patients with advanced cutaneous squamous cell carcinoma in Italy

Ghetti G, D’Avella MC, Pradelli L. – Clinicoecon Outcomes Res. 2021;13:121-133. Published 2021 Feb 10

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

Bagnasco D, Povero M, Pradelli L, Brussino L, Rolla G, Caminati M, Menzella F, Heffler E, Canonica GW, Paggiaro P, Senna G, Milanese M, Lombardi C, Bucca C, Manfredi A, Canevari RF, Passalacqua G; SANI Network (Severe Asthma Network Italy). – World Allergy Organ J. 2021 Jan 27;14(2):100509

Clinical and Economic Rationale for the Early use of SGLT2 Inhibitors in Patients with Type 2 Diabetes

Mannucci E., Mangia P. P. , Pradelli L. – Farmeconomia. Health economics and therapeutic pathways 2020; 21(S1): 3-20

Assessing the effect of nutrition therapy on rehospitalization rate in malnourished pediatric patients with chronic diseases

Lezo A, Povero M, Pradelli L, Nigro E, Plazzotta C, Lagazio C. – {published online ahead of print, 2020 Nov 14}. JPEN J Parenter Enteral Nutr. 2020;10.1002/jpen.2046

Summary of proceedings and expert consensus statements from the international summit “lipids in parenteral nutrition

Martindale, RG, Berlana, D, Boullata, JI, Cai, W, Calder, PC, Deshpande, GH, Evans, D, Garcia-de-Lorenzo, A, Goulet, OJ, Li, A, Mayer, K, Mundi, MS, Muscaritoli, M, Pradelli, L, Rosenthal, M, Seo, JM, Waitzberg, DL & Klek, S 2020,. – Journal of Parenteral and Enteral Nutrition, vol. 44, no. S1, pp. S7-S20

Pharmacoeconomics of parenteral nutrition with ω-3 fatty acids in hospitalized adults

Pradelli L, Muscaritoli M, Klek S, Martindale RG. – JPEN J Parenter Enteral Nutr. 2020;44 Suppl 1:S68-S73

Ω-3 fatty-acid enriched parenteral nutrition in hospitalized patients: systematic review with meta-analysis and trial sequential analysis

Pradelli L, Mayer K, Klek S, et al. – JPEN J Parenter Enteral Nutr. 2020;44(1):44-57

The global usability score short-form for the simplified assessment of dry powder inhalers (DPIs) usability

Povero M, Turco P, Bonadiman L, Dal Negro RW. – Multidiscip Respir Med. 2020;15(1):659. Published 2020 Jul 21

A computational framework for modeling and studying pertussis epidemiology and vaccination

Castagno P, Pernice S, Ghetti G, et al. – BMC Bioinformatics. 2020;21(Suppl 8):344. Published 2020 Sep 16

Funding innovation thanks to anti-tnf-α biosimilars uptake: the economic impact in Italy

Povero M, Pradelli P. – Farmeconomia. Health economics and therapeutic pathways 2020; 21(1): 37-47

Patients’ usability of seven most used dry-powder inhalers in COPD

Dal Negro RW, Turco P, Povero M. – Multidisciplinary respiratory medicine (2019). 14(1)

Acute cough in italian children: parents’ beliefs, approach to treatment, and the family impact

Dal Negro RW, Zanasi A, Turco P, Povero M. – Multidisciplinary respiratory medicine (2019). 14(1)

Effectiveness of long-acting injectable antipsychotics in schizophrenia: a literature review and bayesian meta-analysis informing economic considerations

Zaniolo O, Ghetti G, Povero M, Pradelli L. – Farmeconomia. Health economics and therapeutic pathways 2019; 20(1): 13-24

Cost-utility of surgical sutureless bioprostheses vs tavi in aortic valve replacement for patients at intermediate and high surgical risk

Povero M, Miceli A, Pradelli L, Ferrarini M, Pinciroli M, Glauber M. – Clinicoecon Outcomes Res 2018 Nov 8;10:733-745

Economic burden of hospital malnutrition and the cost-benefit of supplemental parenteral nutrition in critically ill patients in latin america

Correia MITD, Perman MI, Pradelli L, Omaralsaleh AJ, Waitzberg DL. – J Med Econ 2018 Nov;21(11):1047-1056

Propofol vs. Inhalational agents to maintain general anaesthesia in ambulatory and in-patient surgery: a systematic review and meta-analysis

Schraag S, Pradelli L, Alsaleh AJO, Bellone M, Ghetti G, Chung TL, Westphal M, Rehberg S. – BMC Anesthesiol 2018 Nov 8;18(1):162

Cost of influenza and influenza-like syndromes (I-LSs) in Italy: results of a cross-sectional telephone survey on a representative sample of general population

Dal Negro RW, Turco P, Povero M. – Respiratory Medicine, Volume 141, 144-149

Influenza and influenza-like syndromes: the subjects’ beliefs, the attitude to prevention and treatment, and the impact in italian general population

Dal Negro RW, Zanasi A, Turco P, Povero M. – Multidisciplinary Respiratory Medicine (2018) 13:7

Cost of acute cough in italian children

Dal Negro RW, Turco P, Povero M. – ClinicoEconomics and Outcomes Research 2018:10 529–537

Estimating the cost-effectiveness of treatment for prevention of thromboembolic events in at-risk adults with non-valvular atrial fibrillation

Bellone M, Pradelli L, Bo M. – Farmeconomia. Health economics and therapeutic pathways 2018; 19(1): 11-20

Albutrepenonacog alfa (idelvion®) for the treatment of italian patients with hemophilia b: a budget impact model

Pradelli L, Villa S, Castaman G. – Farmeconomia. Health economics and therapeutic pathways 2018; 19(1): 1-10

Propofol or benzodiazepines for short- and long-term sedation in intensive care units? An economic evaluation based on meta-analytic results

Pradelli L, Povero M, Bürkle H, Kampmeier TG, Della-Rocca G, Feuersenger A, Baron JF, Westphal M. – Clinicoecon Outcomes Res. 2017 Nov 9;9:685-698

Parenteral nutrition including an omega-3 fatty-acid-containing lipid emulsion for intensive care patients in China: a pharmacoeconomic analysis

Feng Y, Li C, Zhang T, Pradelli L. – Clinicoecon Outcomes Res. 2017 Sep 5;9:547-555

Lipids in the intensive care unit: recommendations from the ESPEN expert group

Calder PC, Adolph M, Deutz NE, Grau T, Innes JK, Klek S, Lev S, Mayer K, Michael-Titus AT, Pradelli L, Puder M, Vlaardingerbroek H, Singer P. – Clin Nutr. 2017 Sep 7. pii: S0261-5614(17)30315-1

Overall effectiveness of pneumococcal conjugate vaccines: an economic analysis of PHID-CV and PCV-13 in the immunization of infants in Italy

Castiglia P, Pradelli L, Castagna S, Freguglia V, Palù G, Esposito S. – Hum Vaccin Immunother. 2017 Oct 3; 13(10): 2307-2315

A cost-effectiveness analysis of E/C/F/TAF vs three boosted regimens in the italian context

Pradelli L, Di Perri G, Rizzardini G, Martelli E, Giardina S, Povero M. – Farmeconomia. Health economics and therapeutic pathways 2017; 18(1): 113-127